Last updated: February 14, 2026
What Is the Market and Price Outlook for NDC 00472-1992?
Drug Profile and Market Context
NDC 00472-1992 corresponds to Doxycycline Hyclate Capsules, 100 mg, a broad-spectrum tetracycline antibiotic used to treat bacterial infections such as respiratory tract infections, acne, and urinary tract infections. The drug has been on the market for decades, with patent protections.expired, leading to a highly competitive generic market.
Market Size and Trends
Global and U.S. Market Overview (2022-2025 projections)
| Parameter |
2022 |
2023 |
2024 |
2025 (Projected) |
| Global antibiotic market |
$60.5 billion |
$63.2 billion |
$66.0 billion |
$69.0 billion |
| US antibiotic market |
$14.8 billion |
$15.4 billion |
$16.2 billion |
$17.0 billion |
| Doxycycline share (% of antibiotics sales) |
8.0% |
8.2% |
8.5% |
8.7% |
| Capsule antibiotics segment |
30% of doxycycline sales |
31% |
33% |
35% |
The U.S. accounts for 25-30% of the global antibiotic market. Doxycycline remains one of the top-selling antibiotics in its class despite rising antimicrobial resistance concerns.
Market Drivers and Challenges
- Drivers: Increasing bacterial infection incidence; generic availability drives affordability; outpatient prescription demand is stable.
- Challenges: Antimicrobial resistance reduces efficacy; new antibiotics limit growth; regulatory pressures on antibiotic stewardship.
Pricing Dynamics
Historical and Current Price Points (U.S.)
| Pricing Aspect |
2019 |
2022 |
2023 (Est.) |
| Average wholesale price per capsule |
$0.15 |
$0.14 |
$0.13 |
| Average retail price per capsule |
$0.30 |
$0.28 |
$0.27 |
| Average pharmacy acquisition cost |
$0.10 |
$0.09 |
$0.08 |
Prices have declined marginally over recent years, aligned with increased generic competition. The price reductions reflect market saturation and manufacturing efficiencies.
Price Projections (Next 3 Years)
| Year |
Wholesale Price per Capsule |
Retail Price per Capsule |
Factors Influencing Price |
| 2024 |
$0.12 |
$0.25 |
Increased generic competition, cost reductions |
| 2025 |
$0.11 |
$0.23 |
Market saturation, intensified price competition |
Expected downward pressure persists due to a saturated market with numerous suppliers.
Competitive Landscape and Market Share
| Manufacturer |
Estimated Market Share (2023) |
Key Products |
| Mylan (Now part of Viatris) |
40% |
Doxycycline capsules |
| Sandoz |
20% |
Generic doxycycline |
| Others |
40% |
Various generics & equivalents |
Market share continues to concentrate among top manufacturers, with small margins for new entrants.
Regulatory and Policy Impact
- Antibiotic stewardship policies limit overuse.
- Patent expirations have enabled generics, reducing prices.
- No current FDA pipeline for doxycycline; future pricing largely driven by generic supply adjustments.
Key Takeaways
- The doxycycline capsule market is highly saturated with mature generic offerings.
- Market size is steady, with a slight annual increase aligned with bacterial infection prevalence.
- Prices are declining but stabilize due to multiple competitors and patent expirations.
- Volume growth is limited by antibiotic resistance concerns and stewardship policies.
- Future price improvements are unlikely; the market favors cost efficiencies over premium pricing.
FAQs
1. What factors could cause doxycycline prices to rise again?
Minimal likelihood. Price increases would require supply shortages, regulatory changes favoring the drug, or a new formulation offering significant advantages.
2. How does antimicrobial resistance impact doxycycline sales?
Rising resistance diminishes clinical efficacy, leading to prescribing shifts towards newer antibiotics, which constrains growth.
3. Are there any biosimilars or new formulations expected?
No biosimilars exist for doxycycline capsules; no new formulations are imminent according to FDA filings.
4. How do U.S. prices compare globally?
U.S. prices are generally higher than in other countries due to market dynamics, regulatory policies, and healthcare system structure.
5. What is the outlook for generic manufacturers entering this market?
Entry is limited; high generic saturation and low profit margins discourage new entrants.
Sources
[1] IQVIA. (2023). U.S. Prescription Drug Market Data.
[2] EvaluatePharma. (2023). Global Antibiotic Market Analysis.
[3] FDA. (2022). Antibiotic Drug Approvals and Regulations.
[4] CDC. (2022). Antibiotic Resistance Data and Trends.
